The gene polymorphism of beta1-adrenoreceptor, postinfarction myocardial remodeling and cardiovascular risk: is there any correlation?
https://doi.org/10.21518/2079-701X-2018-5-42-46
Abstract
The influence of gene polymorphisms ADRB1 (Ser49Gly), ADRB1 (Arg389Gly) on myocardial remodeling and 12-month prognosis of patients with ST-segment elevation myocardial infarction (STEMI) was studied. The gene polymorphisms ADRB1 (Ser49Gly) and ADRB1 (Arg389Gly) does not affect myocardial remodeling. Ser49 allele is associated with a greater incidence of acute coronary events, such as death from cardiovascular causes, repeated non-fatal myocardial infarction, unplanned coronary revascularization, hospitalization for progressive angina pectoris within a year after STEMI. The Gly49 allele and the Gly49Gly genotype are associated with a favorable prognosis within a year after STEMI. The gene polymorphism ADRB1 (Arg389Gly) does not affect the prognosis after STEMI.
About the Authors
S. S. Yakushin
Ryazan State Medical University
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
M. V. Solodun
Ryazan State Medical University
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Yakushin SS, Filippov EV. Strategic directions for the primary prevention of cardiovascular diseases. Nauka Molodykh (Eruditio Juvenium), 2014, 4: 55–68.
2. Nikulina NN, Yakushin SS. Modern aspects of the diagnosis formulation and statistical recording of myocardial infarction. Kardiologiya, 2016, 56 (9): 60–66.
3. Bellil S, Yakushin SS, Aksentyev SB, Yunevich DS. Comparative prognosis in elderly and senile patients who undergone myocardial infarction with ST-segment elevation within 12-month follow-up period depending on different reperfusion therapy regimens. Rossiyskiy Mediko-biologicheskiy Vestnik Im. Akademika I.P. Pavlova, 2015, 1: 90–94
4. Pacanowski AM, Johnson JA. ADRB1 Gene Summary. Pharmacological reviews, 2007, 59 (1): 2–4.
5. Muszkat M, Stein CM. Pharmacogenetics and res ponse to beta–adrenergic receptor antagonists in heart failure. Clin Pharmacol Ther, 2005, 77 (3): 123–126.
6. Solodun MV. Pharmacotherapy for myocardial infarction: the contribution of genetic factors. Rossiyskiy Kardiologicheskiy Zhurnal, 2016, 3 (131): 110-115.
7. Akhter SA, D’Souza KM, Petrashevskaya NN, Mialet-Perez J, Liggett SB. Myocardial beta-1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am J Physiol Heart Circ Physiol, 2006, 290: 1427–1432.
8. Hakalahti AE, Tapanainen JM, Junttila JM, Kaikko nen KS, Huikuri HV, Petäjä-Repo UE. Association of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction. Cardiovascular Diabetology, 2010, 9 (42): 1–7.
9. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A. et al. Вeta1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med, 2003, 9: 1300–1305.
10. McLean RC, Hirsch GA, Becker LC, Kasch-Semenza L, Gerstenblith G, Schulman SP. Polymorphisms of the beta adrenergic receptor predict left ventricular remodeling following acute myocardial infarction. Cardiovasc Drugs Ther., 2011,25 (3): 251–258.
11. Terra Steven G, Pauly Daniel F, Lee Craig R, Patterson J Herbert, Adams Kirkwood F, Schofield Richard S et al. Вeta-аdrenergic receptor polymorphisms and responses during titration of metoprolol controlled release / extended release in heart failure. Clin Pharmacol Ther, 2005, 77 (3): 127–137.
12. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arhythmogenesis, prognosis, and response to beta-blocker therapy. J Am Coll Cardiol, 2008, 52 (8): 644–651.
13. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R et al. An evaluation of the beta–1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT–HF sub-study, 2003, 5 (4): 463–468.
14. Magnusson Y, Levin MC, Eggertsen R. Ser49Gly of beta1-adrenergic receptor is associated with effective betablocker dose in dilated cardiomyopathy. Clin Pharmaco. Ther, 2005, 78 (3): 221–231.
15. Börjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J, 2000, 21: 1853–1858.
Review
For citations:
Yakushin SS, Solodun MV. The gene polymorphism of beta1-adrenoreceptor, postinfarction myocardial remodeling and cardiovascular risk: is there any correlation? Meditsinskiy sovet = Medical Council. 2018;(5):42-46. (In Russ.) https://doi.org/10.21518/2079-701X-2018-5-42-46
Views:
647
Email this article 